What is OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) is a platinum-based chemotherapy medication formulated as a concentrate for solution for infusion. It contains 50 mg of the active ingredient Oxaliplatin in 10 ml of solution and is intended for intravenous use after appropriate dilution. This medication is widely used in the treatment of various forms of colorectal cancer.
- Active Ingredient: Oxaliplatin (a third-generation platinum compound).
- Form: Concentrate for solution for infusion in a 10 ml glass vial.
- Indications: Primarily used in combination chemotherapy regimens for the treatment of metastatic colorectal cancer and as an adjuvant treatment following resection of stage III colon cancer.
- Drug Classification: Antineoplastic agent – platinum derivative.
- Combination Use: Most commonly administered with 5-fluorouracil (5-FU) and leucovorin (LV) as part of FOLFOX regimens.
- Mechanism: Works by inhibiting DNA synthesis, leading to cell death in rapidly dividing cancer cells.
How to use OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
OXALIPLATIN HOSPIRA must be administered in a clinical setting under the supervision of healthcare professionals experienced in cancer chemotherapy. It requires proper preparation and patient monitoring throughout treatment.
- Dilution Instructions: Must be diluted with 5% dextrose solution. Do not use chloride-containing solutions (e.g., saline), as these can degrade oxaliplatin.
- Route of Administration: Intravenous infusion. Administered over 2 to 6 hours depending on protocol.
- Preparation Precautions: Use aseptic technique during preparation. Healthcare workers should use gloves and protective garments when handling.
- Cycle Frequency: Typically administered once every 2 weeks in combination with other chemotherapy agents.
- Premedication: Antiemetics (such as 5-HT3 antagonists) are usually given prior to administration to reduce nausea and vomiting.
- Cold Sensitivity: Patients should avoid cold drinks, foods, and environments during and after treatment to reduce neuropathic symptoms.
- Monitoring: Regular blood tests and renal/hepatic function assessments are required before each cycle.
Mode of Action OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
Oxaliplatin exerts its antitumor effects by interfering with DNA replication and transcription in cancer cells, ultimately causing cell death.
- Platinum-DNA Adducts: Oxaliplatin forms reactive platinum complexes that bind to DNA, creating intra- and interstrand crosslinks.
- Inhibition of DNA Functions: These crosslinks block DNA polymerase activity, inhibiting DNA replication and transcription.
- Cell Death: DNA damage activates multiple cellular repair pathways. When repair fails, cells undergo apoptosis (programmed cell death).
- Carrier Ligand (DACH): The diaminocyclohexane ligand in oxaliplatin modifies its pharmacological profile and contributes to its unique antitumor efficacy and side effect spectrum.
- Non-Cross Resistance: Due to structural differences from cisplatin and carboplatin, oxaliplatin can be effective in tumors resistant to those drugs.
- Synergy: When used with 5-FU and leucovorin, the cytotoxic effect is significantly enhanced due to combined DNA damage and metabolic interference.
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) Interactions OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
Oxaliplatin may interact with a variety of medications, influencing both efficacy and toxicity. These interactions must be reviewed and managed carefully.
- Other Chemotherapy Agents: Commonly combined with 5-FU and leucovorin; the combination may increase toxicity, particularly myelosuppression and GI effects.
- Nephrotoxic Agents: Co-administration with drugs like aminoglycosides or NSAIDs may increase renal toxicity. Renal function should be closely monitored.
- Neurotoxic Agents: Concomitant use with drugs such as paclitaxel or vincristine may exacerbate neuropathy.
- Anticoagulants: Increased risk of bleeding due to thrombocytopenia. INR and bleeding signs should be monitored in patients on warfarin or similar agents.
- Live Vaccines: Avoid due to immunosuppression from chemotherapy, which could increase infection risk.
- CYP Enzyme Interactions: Oxaliplatin is not significantly metabolized by CYP enzymes, so drug interactions via this pathway are minimal.
Dosage of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
The dosage of oxaliplatin is individualized based on body surface area (BSA), treatment regimen, and patient tolerance. Close clinical and laboratory monitoring is necessary throughout the treatment course.
- Typical Adult Dose: 85 mg/m² every two weeks in combination with 5-FU and leucovorin.
- Adjuvant Setting: Same dosing used for colon cancer in post-operative patients, typically for 6 months.
- Metastatic Setting: Duration of therapy is based on response and tolerability, often continued until disease progression or unacceptable toxicity.
- Dose Adjustments: Required in patients with hematologic toxicity, liver dysfunction, or renal impairment.
- Renal Function: Use caution in patients with creatinine clearance below 30 ml/min. Consider dose reduction or alternative therapy.
- Pediatric Use: Not established. Use is off-label and guided by specialist judgment.
- Missed Dose: Should only be managed by healthcare professionals. Treatment may be delayed rather than skipped, based on lab values.
Possible side effects of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
Oxaliplatin therapy is associated with a predictable but manageable side effect profile. These may be acute or cumulative over successive cycles.
- Neuropathy: Acute cold-induced paresthesia and chronic cumulative sensory neuropathy are hallmark side effects. These may persist after treatment discontinuation.
- Hematological: Includes neutropenia, anemia, and thrombocytopenia. Risk of infection and bleeding should be closely monitored.
- Gastrointestinal: Nausea, vomiting, diarrhea, and stomatitis are common. Antiemetics and hydration support are usually effective.
- Fatigue: Frequently reported and may be debilitating in some patients.
- Hypersensitivity Reactions: Includes rash, fever, bronchospasm, or even anaphylaxis. May occur during any cycle of treatment.
- Hepatic Effects: Mild elevations in liver enzymes; rare reports of hepatic veno-occlusive disease.
- Pulmonary Toxicity: Rare but serious, including interstitial lung disease or fibrosis.
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) Contraindications OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
Patients should be evaluated for contraindications prior to initiating oxaliplatin therapy. Use in contraindicated individuals can lead to severe or fatal outcomes.
- Hypersensitivity: Known allergy to oxaliplatin or other platinum-containing compounds.
- Severe Renal Impairment: Contraindicated in patients with creatinine clearance <30 ml/min due to increased risk of toxicity.
- Pregnancy: Teratogenic and fetotoxic. Use is contraindicated unless benefits outweigh risks. Effective contraception is required.
- Lactation: Breastfeeding should be discontinued during treatment due to potential harm to the infant.
- Pre-existing Severe Neuropathy: Patients with significant baseline peripheral neuropathy should not receive oxaliplatin.
- Severe Bone Marrow Suppression: Contraindicated in patients with unresolved severe neutropenia or thrombocytopenia.
Storage of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml)
Proper storage is essential to preserve the stability, sterility, and efficacy of the medication.
- Temperature: Store between 2°C and 8°C in a refrigerator. Do not freeze.
- Light Protection: Store in original packaging to protect from light, which can degrade the active ingredient.
- Stability: The unopened vial is stable until the expiration date under recommended conditions.
- Post-Dilution Stability: After dilution in 5% dextrose, the solution should be used immediately. If necessary, it may be stored for up to 24 hours at 2–8°C.
- Disposal: As a cytotoxic agent, unused product and waste must be disposed of in accordance with local hazardous waste protocols.
- Handling Precautions: Trained personnel using gloves and protective gear must handle the product to prevent accidental exposure.
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) features an exceptional active ingredient renowned for its potent effects, comprising Oxaliplatin. This powerful formulation provides a superior solution for addressing diverse health concerns. With 5mg/ml concentration and an easily manageable Infusion/Concentrate for, it remains a preferred option for countless individuals seeking effective treatment.
Introduction
All you need to know about OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) .
Welcome to Dwaey, specifically on OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) page.
This medicine contains an important and useful components, as it consists of Oxaliplatin.
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) is available in the market in concentration 5mg/ml and in the form of Infusion/Concentrate for.
HOSPIRA UK LIMITED is the producer of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) and it is imported from UK,
The most popular alternatives of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) are listed downward .
-
Active Substance
-
Size
-
Indications
-
Type
-
Company
Frequently Asked Questions
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) should be stored according to the instructions provided by HOSPIRA UK LIMITED.
In general, it is recommended to store OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) in a cool, dry place, away from direct sunlight
and out of the reach of children.
The duration of treatment with OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) may vary depending on the condition being treated
and the guidance of your healthcare provider. It is important to follow the prescribed treatment
plan and continue taking OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) for the recommended duration, even if your symptoms improve.
If you have any concerns or questions about the duration of treatment, consult your healthcare provider.
It is important to check with your healthcare provider or read the medication label for specific
instructions regarding alcohol consumption while taking OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) . Some medications, including
OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) , may have interactions with alcohol that can reduce effectiveness, increase side
effects, or pose other risks to your health. It is best to follow the guidance provided by your
healthcare professional.
If you miss a dose of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) , take it as soon as you remember. However, if it is close
to the time for your next scheduled dose, skip the missed dose and continue with your regular dosing
schedule. Do not take a double dose to make up for a missed one unless advised by your healthcare provider.
No, do not stop taking OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) without consulting your healthcare provider, even if your
symptoms improve. It is important to complete the full course of treatment as prescribed. Stopping
the medication prematurely may lead to a relapse or incomplete resolution of the condition. If you
have concerns about the duration of treatment, consult your healthcare provider for guidance.
It is important to consult your healthcare provider before taking OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) if you are
pregnant or breastfeeding. They will be able to assess the potential risks and benefits based on your
specific situation. Please note that the safety and suitability of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) during pregnancy
or breastfeeding may depend on the active substance [Active Substance], concentration 5mg/ml,
and the specific recommendations of HOSPIRA UK LIMITED.
The effects of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) on your ability to drive or operate machinery can vary depending on
the active substance [Active Substance], concentration 5mg/ml, and individual factors.
Some medications may cause drowsiness, dizziness, or other side effects that can impair your judgment
or coordination. It is important to read the medication label or consult your healthcare provider to
understand any potential effects on your ability to perform tasks that require alertness.
The instructions for taking OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) with or without food may vary depending on the medication
and the recommendations of HOSPIRA UK LIMITED. Some medications may be more effective when taken with
food to enhance absorption or reduce stomach irritation, while others may need to be taken on an empty
stomach for optimal absorption. Read the medication label or consult your healthcare provider for specific instructions.
The use of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) in children or elderly individuals may depend on various factors, including
the specific medication, type Infusion/Concentrate for, and the recommendations of HOSPIRA UK LIMITED. Some
medications may have specific dosing instructions or precautions for these age groups. Consult your
healthcare provider or read the medication label for information regarding the safe and appropriate use
of OXALIPLATIN HOSPIRA 5mg/ml (50mg/10ml) in children or elderly individuals.
Dwaey
All medical information published on the Dwaey website aims to increase medical awareness and health education among users. However, it is not a substitute for professional medical advice. Always consult with a specialist doctor. We strongly advise against using any information or medicine found on the site without referring to your healthcare provider.
Related Products
0 Comments